Awakn Life Sciences Corp.: Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial
Phase III Trial Will Assess Ketamine-Assisted Therapy for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: